人前列腺癌细胞LAPC-4
BLUEFBIO™ Product Sheet
|
细胞名称 |
人前列腺癌细胞LAPC-4 |
|
|
|
货物编码 |
BFN60807556 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 2类 |
||
|
培养体系 |
90%DMEM+10%FBS+1%双抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人前列腺癌细胞LAPC-4取自男性前列腺癌淋巴转移组织。 |
||
|
注释 |
Doubling time: ~72 hours; 60.87 hours (https://www.synapse.org/#!Synapse:syn2347014). Karyotypic information: Has lost chromosome Y. Omics: Array-based CGH. Omics: Deep RNAseq analysis. Omics: Transcriptome analysis. |
||
|
基因突变 |
TP53 p.Arg175His (c.524G>A) (PubMed=14518029). |
||
|
HLA信息 |
/ |
||
|
STR信息 |
Amelogenin X,Y CSF1PO 12,13 D3S1358 15,17 D5S818 12 (ATCC) 11,13 (PubMed=14518029) D7S820 10,10.3,11 (ATCC) 11 (PubMed=14518029) D8S1179 13 D13S317 9,10,11,12 (ATCC) 10,12 (PubMed=14518029) D16S539 9 D18S51 14,15,22 D21S11 28,30 FGA 21,22 TH01 6,9.3 TPOX 8 vWA 15,16 (ATCC) 16 (PubMed=14518029) |
||
|
参考文献 |
Patent=US6365797 Sawyers C.L., Klein K.A., Witte O.N., Reiter R.E. Mice models of human prostate cancer progression. Patent number US6365797, 02-Apr-2002
PubMed=12725112; DOI=10.1385/1-59259-372-0:21 Russell P.J., Kingsley E.A. Human prostate cancer cell lines. Methods Mol. Med. 81:21-39(2003)
PubMed=14518029; DOI=10.1002/pros.10290 van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225(2003)
PubMed=15486987; DOI=10.1002/pros.20158 Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63:187-197(2005)
PubMed=25960936; DOI=10.4161/21624011.2014.954893 Boegel S., Lower M., Bukur T., Sahin U., Castle J.C. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology 3:E954893-E954893(2014)
PubMed=28145883; DOI=10.18632/oncotarget.14850 Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget 8:18949-18967(2017) |
||
